- Neurocrine Biosciences (NBIX, Financial) reports success in Phase 4 KINECT-PRO study for tardive dyskinesia treatment.
- INGREZZA® showed improvements in patient-reported outcomes in physical, social, and emotional functions.
- The study revealed significant benefits as early as Week 4, sustained through Week 24, with a high completion rate of 88%.
Neurocrine Biosciences (NBIX) has announced positive outcomes from their Phase 4 KINECT-PRO study, investigating the effects of INGREZZA® (valbenazine) in treating tardive dyskinesia. The open-label trial, including 59 participants, demonstrated robust enhancements in physical, social, and emotional aspects of daily life, with improvements evident as early as the fourth week and maintained through the 24th week of treatment. A remarkable 52 out of 59 patients successfully completed the study.
The study is notable as it specifically assesses patient-reported improvements with the treatment of a vesicular monoamine transporter 2 (VMAT2) inhibitor using multiple validated scales, such as the Tardive Dyskinesia Impact Scale (TDIS), Sheehan Disability Scale (SDS), and EQ Visual Analogue Scale (EQ-VAS), amongst others. By Week 24, the overall population registered a mean change of -8.0 points in the TDIS score and a +13.1 enhancement in the EQ-VAS score, demonstrating meaningful advancements in patients' quality of life.
The KINECT-PRO study also reveals INGREZZA's consistent safety profile with no new safety concerns, reinforcing the treatment's favorable risk-benefit ratio. The results highlight the potential for INGREZZA to address the needs of an underappreciated patient group, potentially expanding its market through earlier intervention strategies.
These insights support the clinical utility of INGREZZA across varying severities of tardive dyskinesia, underscoring the therapeutic's comprehensive value in managing this challenging condition.
